|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Current assets held for sale | ||||||||||||||||||||
| Advance due from related entity | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Branding Agreement | ||||||||||||||||||||
| Investment | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intellectual property | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accounts payable to related parties | ||||||||||||||||||||
| Advances from related parties | ||||||||||||||||||||
| Advances payable | ||||||||||||||||||||
| Advances payable - related parties | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Accrued liabilities - related parties | ||||||||||||||||||||
| Interest payable | ||||||||||||||||||||
| Interest payable to related parties | ||||||||||||||||||||
| Notes payable | ||||||||||||||||||||
| Convertible notes, net of discounts | ||||||||||||||||||||
| Convertible notes to related parties, net of discounts | ||||||||||||||||||||
| Derivative liabilities | ||||||||||||||||||||
| Current liabilities held for sale | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Preferred stock, value | ||||||||||||||||||||
| Preferred stock - Series A | ||||||||||||||||||||
| Preferred stock - Series B | ||||||||||||||||||||
| Total preferred stock, value | ||||||||||||||||||||
| Common stock - 5,000,000,000 shares authorized, $0.001 par value, 2,435,717,463 and 678,796,778 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total controlling interest | ||||||||||||||||||||
| Non-controlling interest | ||||||||||||||||||||
| Total stockholders' deficit | ||||||||||||||||||||
| Total liabilities and stockholders' deficit | ||||||||||||||||||||
Loading...
